1. Home
  2. DVA vs RGLD Comparison

DVA vs RGLD Comparison

Compare DVA & RGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVA
  • RGLD
  • Stock Information
  • Founded
  • DVA 1994
  • RGLD 1981
  • Country
  • DVA United States
  • RGLD United States
  • Employees
  • DVA N/A
  • RGLD N/A
  • Industry
  • DVA Misc Health and Biotechnology Services
  • RGLD Precious Metals
  • Sector
  • DVA Health Care
  • RGLD Industrials
  • Exchange
  • DVA Nasdaq
  • RGLD Nasdaq
  • Market Cap
  • DVA 9.7B
  • RGLD 10.6B
  • IPO Year
  • DVA 1995
  • RGLD N/A
  • Fundamental
  • Price
  • DVA $130.10
  • RGLD $190.59
  • Analyst Decision
  • DVA Hold
  • RGLD Buy
  • Analyst Count
  • DVA 3
  • RGLD 6
  • Target Price
  • DVA $154.67
  • RGLD $191.50
  • AVG Volume (30 Days)
  • DVA 663.6K
  • RGLD 715.9K
  • Earning Date
  • DVA 10-28-2025
  • RGLD 11-05-2025
  • Dividend Yield
  • DVA N/A
  • RGLD 0.94%
  • EPS Growth
  • DVA 8.72
  • RGLD 86.84
  • EPS
  • DVA 10.20
  • RGLD 6.82
  • Revenue
  • DVA $13,161,328,000.00
  • RGLD $791,923,000.00
  • Revenue This Year
  • DVA $5.96
  • RGLD $18.29
  • Revenue Next Year
  • DVA $3.54
  • RGLD $18.17
  • P/E Ratio
  • DVA $12.76
  • RGLD $28.04
  • Revenue Growth
  • DVA 5.09
  • RGLD 30.42
  • 52 Week Low
  • DVA $126.07
  • RGLD $130.67
  • 52 Week High
  • DVA $179.60
  • RGLD $196.00
  • Technical
  • Relative Strength Index (RSI)
  • DVA 38.72
  • RGLD 66.26
  • Support Level
  • DVA $131.77
  • RGLD $184.20
  • Resistance Level
  • DVA $137.58
  • RGLD $187.91
  • Average True Range (ATR)
  • DVA 2.61
  • RGLD 4.14
  • MACD
  • DVA -0.54
  • RGLD 0.79
  • Stochastic Oscillator
  • DVA 4.45
  • RGLD 74.58

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

About RGLD Royal Gold Inc.

Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.

Share on Social Networks: